(VIANEWS) – Shares of Inovio Pharmaceuticals (NASDAQ: INO) rose by a staggering 31.69% in 21 sessions from $1.83 at 2022-10-17, to $2.41 at 11:43 EST on Monday, following the last session’s downward trend. NASDAQ is falling 0.67% to $11,247.78, after two successive sessions in a row of gains.

Inovio Pharmaceuticals’s last close was $2.35, 69.76% below its 52-week high of $7.77.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. is a biotechnology firm that focuses on developing, commercializing, and marketing DNA medicines. These drugs are used to protect and treat people against diseases such as cancer, human papillomavirus, and other infectious diseases. The DNA medicines platform utilizes precisely-designed SynCon to identify and optimize DNA sequences of target antigens. CELLECTRA smart device technology facilitates the delivery of DNA plasmids. It plans clinical trials of DNA medicines to treat HPV-associated diseases, including anal and cervical dysplasia, vulvar and cervical precancers; HPV associated cancers such as cervical and anal papillomatosis, head and neck cancer, vaginal cancer, HIV, Ebola, Middle East Respiratory syndrome (MERS), and Lassa fever. ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, (DARPA), Defense Advanced Research Projects Agency, Defense Advanced Research Projects Agency, Department of Defense (DoD), HIV Vaccines Trial Network, Kaneka Eurogentec, Medical CBRN Defense Consortium, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals, Thero Fisher Scientific, The Wistar Institute of Research, Thermo Fisher Military Institute of Research, University of Research, Walter Reed Army Institute of Research, University of Research, University of Research, Thermo Fisher Research, and Thermo Fisher to support thero Fisher Scientific, Thermo Fisher Research, Thermo Fisher Research, and Thermo Fisher a Fisher Scientific, Thermo Fisher a To support the investigational DNA vaccine, INO-4800 for COVID-19, Richter-Helm BioLogics GmbH & Co. KG has been entered into an agreement. The partnership also includes International Vaccine Institute (Seoul National University Hospital) and Regeneron Pharmaceuticals. Plymouth Meeting is the headquarters of this company, which was established in 1979.

Earnings per Share

Inovio Pharmaceuticals’ trailing 12 months profit per share was $-1.073.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -87.99%.

Sales Growth

Inovio Pharmaceuticals’s sales growth is negative 36.1% for the current quarter and negative 17.8% for the next.

Growth Estimates Quarters

For the current quarter, the company expects a decline of 3.4% in growth and a rise of 46% the following.

Moving Average

Inovio Pharmaceuticals’s value is much higher than its 50-day average moving average $1.92, and lower than its 200-day average moving average $2.46.

More news about Inovio Pharmaceuticals (INO).

LEAVE A REPLY

Please enter your comment!
Please enter your name here